Radiation therapy for prostate cancer in Syrian refugees: facing the need for change.
Syria
Turkey
global health
prostate cancer
radiation therapy
refugee
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
02
2023
accepted:
11
05
2023
medline:
19
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
To report the utilization of radiation therapy in Syrian refugee patients with prostate cancer residing in Turkey. A multi-institutional retrospective review including 14 cancer centers in Turkey was conducted to include 137 Syrian refugee patients with prostate cancer treated with radiation therapy (RT). Toxicity data was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Noncompliance was defined as a patient missing two or more scheduled RT appointments. Advanced disease, defined as stage III or IV, was reported in 64.2% of patients while androgen deprivation therapy (ADT) was only administrated to 20% of patients. Conventionally fractionated RT with a median number of 44 fractions was delivered to all patients with curative intent ( Most Syrian refugee prostate cancer patients presented with advanced disease however ADT was seldom used. Despite the low treatment compliance rate, conventional fractionation was used in all patients. Interventions are critically needed to improve screening and increase the use of standard-of-care treatment paradigms, including hypofractionated RT and ADT.
Identifiants
pubmed: 37325331
doi: 10.3389/fpubh.2023.1172864
pmc: PMC10264678
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1172864Informations de copyright
Copyright © 2023 Eren, Kilic, Eren, Kaplan, Teke, Kutuk, Bicakci, Hathout, Moningi, Orio, Atalar and Sayan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Cancer. 2022 May 12;22(1):532
pubmed: 35550042
J Cancer Educ. 2020 Aug;35(4):709-717
pubmed: 30924080
Turk J Urol. 2022 Jul;48(4):287-293
pubmed: 35913444
World J Urol. 2020 Mar;38(3):681-693
pubmed: 31297628
J Urol. 2019 Mar;201(3):528-534
pubmed: 30759696
Nat Rev Urol. 2021 Nov;18(11):669-685
pubmed: 34389825
PLoS One. 2015 Sep 25;10(9):e0138303
pubmed: 26406317
Lancet. 2004 Nov 27-Dec 3;364(9449):1974-83
pubmed: 15567014
WMJ. 2022 Jul;121(2):141-144
pubmed: 35857690
EClinicalMedicine. 2022 Jun 03;49:101459
pubmed: 35747185
BMC Med Ethics. 2006 Dec 13;7:E13
pubmed: 17166274
Breast J. 2017 Sep;23(5):525-536
pubmed: 28252245
BMC Med Ethics. 2010 Jun 13;11:10
pubmed: 20540803
BMC Health Serv Res. 2019 Jul 23;19(1):513
pubmed: 31337406
J BUON. 2017 Nov-Dec;22(6):1591-1594
pubmed: 29332358
Cochrane Database Syst Rev. 2019 Sep 03;9:CD011462
pubmed: 31476800
Brachytherapy. 2012 Nov-Dec;11(6):441-5
pubmed: 22728157
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Salud Publica Mex. 2019 Jul-Ago;61(4):542-544
pubmed: 31314214
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):563-70
pubmed: 27020104
Value Health. 2022 May;25(5):796-802
pubmed: 35500949
JCO Glob Oncol. 2020 Sep;6:1422-1427
pubmed: 32986515
PLoS One. 2020 Mar 30;15(3):e0230675
pubmed: 32226017
Am Soc Clin Oncol Educ Book. 2018 May 23;38:433-440
pubmed: 30231320
Am J Med Sci. 2008 Apr;335(4):254-9
pubmed: 18461726
Lancet Oncol. 2014 Jun;15(7):e290-7
pubmed: 24872112